Press releases
- Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
- Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
- Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
- Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
- DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
- Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
- Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
More ▼
Key statistics
On Monday, Marinus Pharmaceuticals (MRNS*:MEX) closed at 124.00, 0.00% above its 52-week low of 124.00, set on Apr 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 124.00 |
---|---|
High | 124.00 |
Low | 124.00 |
Bid | 25.00 |
Offer | 160.00 |
Previous close | 124.00 |
Average volume | -- |
---|---|
Shares outstanding | 54.93m |
Free float | 54.40m |
P/E (TTM) | -- |
Market cap | 82.95m USD |
EPS (TTM) | -2.63 USD |
Data delayed at least 20 minutes, as of Apr 15 2024 12:30 BST.
More ▼